journal article·2017-11-01

Control of Carbon Nanotube Solvatochromic Response to Chemotherapeutic Agents

Jackson D. Harvey, Hanan A. Baker, Elizabeth Mercer, Januka Budhathoki-Uprety, Daniel A. Heller

Publisher page

Abstract

Alkylating agents such as cisplatin play an essential role in chemotherapy regimens, but initial and acquired resistance in many cancer types often dampen therapeutic response. The poor understanding of the mechanisms of resistance highlight the need for quantitative measurements of alkylating agent distribution at both the tissue and subcellular levels. Sensors for use in live animals and cells would allow for more effective study of drug action and resistance. Toward this end, single-walled carbon nanotubes suspended with single-stranded DNA have suitable optical properties for in vivo sensors, such as near-infrared emission and sensitivity to the local environment via solvatochromic responses. Currently, solvatochromic changes of such sensors have been limited by the chemical nature of the analyte, making it impossible to control the direction of energy emission changes. Here, we describe a new approach to control the direction and magnitude of solvatochromic responses of carbon nanotubes. We found that the alkylation of DNA on the nanotube surface can result in small changes in DNA conformation that allow the adsorption of amphiphiles to produce large differences (>14 nm) in response to different drugs. The technique surprisingly revealed differences among drugs upon alkylation. The ability to control carbon nanotube solvatochromism as desired may potentially expand the application of nanotube-based optical sensors for new classes of analytes.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Carbon Nanotubes in Composites · Advanced biosensing and bioanalysis techniques · Nanopore and Nanochannel Transport Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States

Weill Cornell Medical College, Cornell University, New York, New York 10065, United States

School of Medicine, Indiana University, Indianapolis, Indiana 46202, United States

Funding

National Cancer Institute · Honorable Tina Brozman Foundation · National Institute of Child Health and Human Development · Memorial Sloan-Kettering Cancer Center · Center for Molecular Imaging and Nanotechnology, Memorial Sloan-Kettering Cancer Center · Byrne Research Fund, Memorial Sloan-Kettering Cancer Center · Commonwealth Foundation for Cancer Research · William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research · Anna Fuller Fund · Imaging and Radiation Sciences Program at Memorial Sloan Kettering Cancer Center · Louis V. Gerstner Jr. Young Investigators Fund, Memorial Sloan-Kettering Cancer Center · Cycle for Survival, Memorial Sloan-Kettering Cancer Center · Expect Miracles Foundation - Financial Services Against Cancer · Experimental Therapeutics Center, Memorial Sloan-Kettering Cancer Center

References (35)

Show source-provided references
1. Eastman A. · Cancer Cells · 1990 · 2 · 275
2. 10.1038/sj.onc.120693310.1038/sj.onc.1206933 ↗
3. Katzung, B. G.; Masters, S. B.; Trevor, A. J.Basic & Clinical Pharmacology,11th ed.McGraw-Hill Medical:New York, 2009; pxiii, 1218 pp.
4. 10.1021/ja00175a02010.1021/ja00175a020 ↗
5. 10.1016/0304-419X(85)90001-010.1016/0304-419X(85)90001-0 ↗
6. 10.1073/pnas.07206799910.1073/pnas.072067999 ↗
7. 10.1038/nrc216710.1038/nrc2167 ↗
8. 10.1038/srep3664110.1038/srep36641 ↗
9. Fichtinger-Schepman A. M. J. · Cancer Res. · 1987 · 47 · 3000
10. 10.1016/S0021-9673(99)00467-710.1016/S0021-9673(99)00467-7 ↗
11. 10.1111/j.1432-1033.1997.00370.x10.1111/j.1432-1033.1997.00370.x ↗
12. 10.1126/science.270.5243.184210.1126/science.270.5243.1842 ↗
13. 10.1021/tx060058c10.1021/tx060058c ↗
14. 10.1126/science.107263110.1126/science.1072631 ↗
15. 10.1063/1.274522810.1063/1.2745228 ↗
16. 10.1016/j.chemphys.2012.11.00310.1016/j.chemphys.2012.11.003 ↗
17. 10.1126/science.112079210.1126/science.1120792 ↗
18. 10.1038/srep1416710.1038/srep14167 ↗
19. 10.1038/nmat87710.1038/nmat877 ↗
20. 10.1002/adhm.20130003310.1002/adhm.201300033 ↗
21. 10.1021/acsnano.7b0017610.1021/acsnano.7b00176 ↗
22. 10.1021/acsnano.5b0543810.1021/acsnano.5b05438 ↗
23. 10.1038/nnano.2013.23610.1038/nnano.2013.236 ↗
24. 10.1038/nnano.2013.22210.1038/nnano.2013.222 ↗
25. 10.1038/s41551-017-004110.1038/s41551-017-0041 ↗
26. 10.1038/nnano.2008.36910.1038/nnano.2008.369 ↗
27. 10.1073/pnas.100551210810.1073/pnas.1005512108 ↗
28. 10.1126/science.107872710.1126/science.1078727 ↗
29. 10.1021/ja504078b10.1021/ja504078b ↗
30. Knox R. J. · Cancer Res. · 1986 · 46 · 1972
31. 10.1016/j.critrevonc.2016.03.01410.1016/j.critrevonc.2016.03.014 ↗
32. Lippert B. · Met Ions Biol. Syst · 1996 · 33 · 105
33. 10.2174/18715200777931408010.2174/187152007779314080 ↗
34. Kelland, L. R.; Farrell, N.Platinum-Based Drugs in Cancer Therapy;Humana Press:Totowa, NJ, 2000; p1(online resource).10.1385/1592590128 ↗
35. 10.1021/acs.analchem.6b0409110.1021/acs.analchem.6b04091 ↗